BD announces wearable injector trial for subcutaneous delivery of biologics
The decision to employ the injector in this first pharmaceutical-sponsored combination product trial comes after positive results from more than 50 pre-clinical and clinical studies carried out by BD.
The company noted that a device clinical trial among these studies highlighted the performance, with all subjects indicating their willingness to use the injector if prescribed.
BD Pharmaceutical Systems worldwide president Patrick Jeukenne said: "This trial demonstrates BD's commitment to helping pharma companies by advancing large-volume injection science, ensuring therapies are accessible and patient-friendly by offering more efficient and convenient options for biologics.
"BD's enhanced testing capabilities acquired through ZebraSci and the proven capabilities of the BD Libertas Wearable Injector technology further position BD as an innovative leader in drug delivery."
The prefilled, patient-ready-to-use system is said to support delivery of high-viscosity biologics of up to 50 centipoise.
It comes in two volume configurations, 2mL to 5mL and 5mL to 10mL, catering to various therapeutic needs.
Additionally, its design features a simple "peel, stick and click" mechanism, eliminating the need for user filling or assembly.
The injector also includes a transparent window for monitoring the drug delivery, push-button activation, along with a colour-coded status indicator.
The company is currently validating fill-finish and final assembly processes with several contract manufacturing organisations (CMOs) to ensure support for pharmaceutical collaborators from development to commercial-scale production.
As a device component intended for drug-device combination products, it is not subject to US Food and Drug Administration (FDA) 510(k) clearance or European Union (EU) CE mark certification.
In April 2025, BD secured the 510(k) clearance for the Phasix ST umbilical hernia patch, enabling the product's commercial launch.
"BD announces wearable injector trial for subcutaneous delivery of biologics" was originally created and published by Medical Device Network, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 hours ago
- Yahoo
Celenese (CE) Extends Losses to 3rd Day on Weak Outlook
We recently published Celanese Corp. (NYSE:CE) is one of the worst-performing stocks on Tuesday. Celanese extended its losing streak to a third straight day on Tuesday, as investor sentiment was dampened by a weak outlook for the rest of the year. In a statement, Celanese Corp. (NYSE:CE) said it expects 'a softening demand environment across most key end-markets in the second half of the year.' 'The company anticipates slowing demand will partially offset the benefits from the cost reduction actions that are expected to be realized in the third quarter. Additionally, [Celanese Corp. (NYSE:CE)] anticipates an approximate $25 million negative sequential impact to earnings due to ongoing inventory reduction efforts,' it said. In the second quarter of the year, Celanese Corp. (NYSE:CE) grew its net income by 28 percent to $199 million from $155 million in the same period last year. Copyright: dolgachov / 123RF Stock Photo Net sales, however, dipped by 4.5 percent to $2.5 billion from $2.65 billion year-on-year. Commenting on the performance, President and CEO Scott Richardson said that he was pleased with the company's earnings results. Despite the more cautious outlook, he was confident that their action plans 'will continue to drive value.' While we acknowledge the potential of CE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
a day ago
- Business Wire
CARMAT Provides an Update on the Ongoing Receivership Procedure
PARIS--(BUSINESS WIRE)--Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the ' Company ' or ' CARMAT '), today provides an update on the ongoing receivership procedure and announces the suspension of trading in CARMAT shares, starting August 14, 2025, before stock market opening, ahead of the court hearing scheduled on August 19, 2025. Update on the ongoing receivership procedure Following a call for public tenders (buyers or investors) initiated as part of the receivership opened on July 1, 2025, the judiciary administrator had received, by the deadline of July 31, 2025, one takeover bid within the context of a sales plan (the 'Bid') 1. This Bid will be assessed by the Versailles Economic Court 2 (the "Court") at a hearing scheduled on August 19, 2025. The Company again draws attention to the fact that there is no guarantee at this stage that this Bid will be successful. The Company also reminds that even if the Bid is validated by the Court, the Company's shareholders and creditors may incur a significant loss of up to the total value of their investment or receivables. CARMAT is subject to a risk of liquidation, including in the short term. Suspension of CARMAT shares trading (ISIN code: FR0010907956, Ticker: ALCAR) Ahead of the court hearing scheduled on August 19, 2025, CARMAT has asked Euronext to suspend the trading of its shares starting on August 14, 2025, before the stock market opens. Another press release will be issued by the Company once the outcome of the court hearing is known. In any case, CARMAT endeavors to provide continuous support to patients who currently benefit from its Aeson® artificial heart. ●●● About CARMAT CARMAT is a French MedTech that designs, manufactures and markets the Aeson ® artificial heart. The Company's ambition is to make Aeson ® the first alternative to a heart transplant, and thus provide a therapeutic solution to people suffering from end-stage biventricular heart failure, who are facing a well-known shortfall in available human grafts. The world's first physiological artificial heart that is highly hemocompatible, pulsatile and self-regulated, Aeson ® could save, every year, the lives of thousands of patients waiting for a heart transplant. The device offers patients quality of life and mobility thanks to its ergonomic and portable external power supply system that is continuously connected to the implanted prosthesis. Aeson ® is commercially available as a bridge to transplant in the European Union and other countries that recognize CE marking. Aeson ® is also currently being assessed within the framework of an Early Feasibility Study (EFS) in the United States. Founded in 2008, CARMAT is based in the Paris region, with its head offices located in Vélizy-Villacoublay and its production site in Bois-d'Arcy. The Company can rely on the talent and expertise of a multidisciplinary team of circa 200 highly specialized people. CARMAT is listed on the Euronext Growth market in Paris (Ticker: ALCAR / ISIN code: FR0010907956). For more information, please go to and follow us on LinkedIn. Disclaimer This press release and the information it contains do not constitute an offer to sell or subscribe, nor a solicitation of an offer to buy or subscribe, for CARMAT shares in any country. This press release may contain forward-looking statements regarding the Company's objectives and outlook. These forward-looking statements are based on the current estimates and anticipations of the Company's management and are subject to risk factors and uncertainties, including those described in its Universal Registration Document filed with the French Financial Markets Authority (Autorité des marchés financiers) (the 'AMF') under number D.25-0345 (the ' 2024 Universal Registration Document '), available free of charge on the websites of CARMAT ( and the AMF ( Readers' attention is particularly drawn to the fact that the Company is currently placed in receivership (opened on July 1, 2025) and is facing a risk of liquidation including in the very short term. The Company is also exposed to other risks and uncertainties, such as its ability to implement its strategy, the pace of development of its production and sales, the progress and results of ongoing or planned clinical trials, technological developments, the competitive landscape, regulatory changes, industrial risks, and all risks related to the management of the Company's growth. Forward-looking statements mentioned in this press release may not be achieved due to these factors or other unknown risks and uncertainties, or risks that the Company does not currently consider to be material or specific. Aeson® is an active implantable medical device commercially available in the European Union and other countries recognising the CE mark. The Aeson® total artificial heart is intended to replace the ventricles of the native heart and is indicated as a bridge to transplant in patients with end-stage biventricular heart failure (Intermacs classes 1-4) who cannot benefit from maximal medical therapy or a left ventricular assist device (LVAD) and who are likely to benefit from a heart transplant within 180 days of implantation. The decision to implant and the surgical procedure must be carried out by healthcare professionals trained by the manufacturer. The documentation (clinician's manual, patient's manual and alarm booklet) must be read carefully to learn about the characteristics of Aeson® and the information required for patient selection and proper use (contraindications, precautions, side effects) of Aeson®. In the United States, Aeson® is currently only available as part of a feasibility clinical trial approved by the Food & Drug Administration (FDA). 1 Offre de reprise en plan de cession » (in French). 2 Tribunal des Activités Economiques de Versailles.
Yahoo
a day ago
- Yahoo
Celanese Corp (CE) Q2 2025 Earnings Call Highlights: Strategic Moves Amid Market Challenges
Release Date: August 12, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Celanese Corp (NYSE:CE) is focused on achieving a $2 per share quarterly EPS run rate through controllable actions such as cost structure improvements and executing differentiated business models. The company is prioritizing free cash flow generation, with a target of $700 million to $800 million for the year, translating to approximately $7 per share. Celanese Corp (NYSE:CE) is actively reducing inventory levels in the Engineered Materials segment through various strategies, including warehouse consolidation and SKU rationalization. The company is leveraging its low-cost production capabilities in the Western Hemisphere, particularly in the acetyls business, to maintain profitability despite challenging market conditions. Celanese Corp (NYSE:CE) is pursuing divestitures, such as the Micromax process, to strengthen its balance sheet and focus on core operations. Negative Points Order books have weakened, particularly in the China automotive sector and European demand, impacting the Engineered Materials segment. The company is experiencing volume weakness in the Western Hemisphere acetyl chain, which has continued into the third quarter. Celanese Corp (NYSE:CE) is facing challenges in achieving price increases in certain Engineered Materials products, with some pricing at unsustainable levels. The acetyls business is impacted by overcapacity in Asia, leading to lower third-party acetic acid sales and margin compression. Visibility on order books is limited, with short-term visibility in both acetyls and Engineered Materials segments, making it difficult to predict future demand accurately. Q & A Highlights Warning! GuruFocus has detected 6 Warning Signs with CE. Q: Can you provide more color on the weakening order books you mentioned, particularly in which end markets this is occurring? A: Scott Richardson, President and CEO, explained that the weakening is primarily seen in China automotive orders and European demand within the Engineered Materials segment. The Americas have remained relatively stable, but there is also volume weakness in the Western Hemisphere's acetyl chain. Q: How do you plan to achieve the $2 per share quarterly EPS run rate, and when do you expect to reach it? A: Scott Richardson stated that the $2 target is achievable through concrete plans focusing on cost structure improvements and executing differentiated business models. The path includes inventory movement, cost actions, and price opportunities in Engineered Materials. The timeline may be delayed due to current demand conditions, but the company is prepared to capitalize on any demand changes. Q: What is the impact of the $25 million inventory reduction in the EM segment for Q3, and is it related to weaker demand? A: Scott Richardson and Chuck Kyrish, CFO, explained that the inventory reduction is part of a multiyear effort to operate with lower inventory levels. The $25 million impact is due to a mix of production campaigns and current demand trends, resulting in a sequential negative earnings impact for Q3. Q: Are tariffs in China affecting your tow business, and how is the VAM and acetic acid business performing in China? A: Scott Richardson confirmed that tariffs are not impacting the tow business as it operates through a joint venture in China. The VAM and acetic acid business is above breakeven, with a focus on downstream products for better value. Some US material is sold in Asia, either directly or through swaps. Q: How do you view the structural challenges in your businesses, and are there any long-term issues affecting earnings power? A: Scott Richardson expressed confidence in the company's actions to increase earnings power and readiness for demand changes. He highlighted cost structure improvements and strategic positioning in the Western Hemisphere as key factors. While some business areas face challenges, the company is focused on continuous improvement and adaptability. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
